Merck Press Releases

Published on July 23, 2015 - 15:29 GMT

Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for grazoprevir/elbasvir (100mg/ …

Distribution channels: Companies

Published on July 23, 2015 - 15:11 GMT

Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for grazoprevir/elbasvir (100mg/ …

Distribution channels: Companies

Published on July 22, 2015 - 17:29 GMT

Merck Announces Fourth-Quarter 2015 Dividend

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.45 per share of the company’s common stock for the fourth quarter of …

Distribution channels: Companies

Published on July 22, 2015 - 11:10 GMT

European Commission Approves Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-treated ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of advanced ( …

Distribution channels: Companies

Published on July 21, 2015 - 12:08 GMT

Merck Marks 30-Year Milestone in Commitment to Innovation and Care in HIV/AIDS

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the company's commitment to HIV and AIDS, which started with a research and development program initiated in the mid-1980s …

Distribution channels: Companies

Published on June 29, 2015 - 12:40 GMT

Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND® (fosaprepitant dimeglumine) for Injection, …

Distribution channels: Companies

Published on June 26, 2015 - 12:09 GMT

Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, July 28. …

Distribution channels: Companies

Published on June 17, 2015 - 16:18 GMT

Merck Manual and MSD Manual Launch Global Medical Knowledge 2020 to Provide Free Access to Credible Medical Information on Every ...

KENILWORTH, N.J. – Merck Manuals (called MSD Manuals outside of the United States and Canada), one of the world’s most widely-used medical resources since 1899, today announced the launch of Global Medical Knowledge 2020 – a worldwide initiative to make …

Distribution channels: Companies

Published on June 11, 2015 - 12:22 GMT

Merck Launches New Program That Encourages Women to “Rule the Real Talk” and Prioritize Their Sexual Health

KENILWORTH, N.J.-– Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the results of a recent on-line survey about women’s views on relationships and sex, which found that women are less assertive about initiating …

Distribution channels: Companies

Published on June 10, 2015 - 13:08 GMT

Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, ...

KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced that pivotal Phase 3 clinical studies of SB4, an investigational biosimilar of …

Distribution channels: Companies

Published on June 10, 2015 - 13:06 GMT

Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, ...

KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced that pivotal Phase 3 clinical studies of SB4, an investigational biosimilar of …

Distribution channels: Companies

Published on June 8, 2015 - 20:31 GMT

TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled study of the …

Distribution channels: Companies

Published on June 3, 2015 - 21:08 GMT

Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment …

Distribution channels: Companies

Published on June 1, 2015 - 21:41 GMT

FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Merck …

Distribution channels: Companies

Published on June 1, 2015 - 21:03 GMT

FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Merck …

Distribution channels: Companies

Published on June 1, 2015 - 12:38 GMT

Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies

KENILWORTH, N.J. & BERKELEY, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Dynavax Technologies Corporation (Nasdaq: DVAX) today announced they have entered into two clinical trial collaboration …

Distribution channels: Companies

Published on June 1, 2015 - 12:38 GMT

Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies

KENILWORTH, N.J. & BERKELEY, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Dynavax Technologies Corporation (Nasdaq: DVAX) today announced they have entered into two clinical trial collaboration …

Distribution channels: Companies

Published on June 1, 2015 - 12:08 GMT

Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in …

Distribution channels: Companies

Published on June 1, 2015 - 12:07 GMT

Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in …

Distribution channels: Companies

Published on May 30, 2015 - 18:05 GMT

TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA® (pembrolizumab)

WALTHAM, Mass., and KENILWORTH, N.J., May 30, 2015 – TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a collaboration to evaluate the …

Distribution channels: Companies

Merck Press Releases Distributed by EIN Presswire